National Institute on Drug Abuse; Notice of Closed Meetings, 5798-5799 [2010-2074]

Download as PDF 5798 Federal Register / Vol. 75, No. 23 / Thursday, February 4, 2010 / Notices srobinson on DSKHWCL6B1PROD with NOTICES microdissection devices outside of North America, cultivating the necessary reputation is a major barrier to competitively significant entry into the North American market. It can take several years to acquire a reputation on par with the current laser microdissection device brands in order to make a significant market impact. Accordingly, entry by a foreign firm is unlikely to make a significant market impact sufficient to counteract any anticompetitive effects from the proposed transaction within the next two years. IV. The Consent Agreement The proposed Consent Agreement eliminates the competitive concerns raised by Danaher’s proposed acquisition of MDS Analytical Technologies by requiring the divestiture of MDS’s assets relating to the manufacture and sale of laser microdissection devices. Danaher and MDS have agreed to sell the Arcturus assets, including the laser microdissection device business, as well as a related reagents business, to Life Technologies within 10 days after the date the Order becomes final. Life Technologies possesses the knowledge, experience, and financial viability to successfully purchase and manage the divestiture assets and replace MDS as an effective competitor in the laser microdissection market. Headquartered in Carlsbad, California, Life Technologies is a life sciences company that manufactures and sells scientific research equipment that it distributes throughout the world. Life Technologies does not currently compete against Danaher and MDS in the sale of laser microdissection devices, but it does manufacture and sell reagents for downstream analysis using tissue samples obtained through laser microdissection. The Arcturus business would be a natural fit into Life Technologies’s product portfolio, since both sets of products are marketed to the same customer base. Pursuant to the Consent Agreement, Life Technologies would receive all the assets necessary to operate MDS’s current laser microdissection business, including equipment used to assemble the Arcturus laser microdissection device, Arcturus software, and reagents that are sold as complementary downstream products to Arcturus customers. In addition to key Arcturus employees, who would be made available to Life Technologies, the Consent Agreement requires MDS to provide Life Technologies with access to certain other employees who may be needed to facilitate the transition of the VerDate Nov<24>2008 17:31 Feb 03, 2010 Jkt 220001 Arcturus laser microdissection assets. The Consent Agreement also requires MDS to transfer all the Arcturus intellectual property, including patent licenses for infrared laser microdissection device technology. Divestiture of all of the Arcturus laser microdissection assets will ensure that Life Technologies has a full line of highquality laser microdissection devices, enabling it to compete immediately with the merged entity. The Commission may appoint an interim monitor to oversee the divestiture of the Arcturus laser microdissection business at any time after the Consent Agreement has been signed. In order to ensure that the Commission remains informed about the status of the proposed divestitures, the proposed Consent Agreement requires the parties to file periodic reports with the Commission until the divestiture is accomplished. If the Commission determines that Danaher has not fully complied with its obligations under the Order within 10 days after the date the Order becomes final, the Commission may appoint a divestiture trustee to divest the Arcturus assets to a Commission-approved acquirer. The purpose of this analysis is to facilitate public comment on the Consent Agreement, and it is not intended to constitute an official interpretation of the proposed Order or the Agreement to Maintain Assets, or to modify their terms in any way. By direction of the Commission. Donald S. Clark, Secretary. [FR Doc. 2010–2460 Filed 2–3–10: 7:15 am] BILLING CODE 6750–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse, Special Emphasis Panel; International Research Collaborations on HIV/AIDS and Drug Use. Date: February 18, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Sofitel Washington DC, Lafayette Square, 806 15th Street, NW., Madeline Room, Washington, DC 20005. Contact Person: Scott Chen, PhD, Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892, 301–443–9511, chensc@mail.nih.gov. Name of Committee: National Institute on Drug Abuse, Special Emphasis Panel, Targeted Library Synthesis and Screening at Novel Targets for Potential Drug Addiction (R21/R33). Date: February 25, 2010. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814. Contact Person: Minna Liang, PhD, Scientific Review Officer, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6101 Executive Blvd., Room 220, MSC 8401, Bethesda, MD 20852, 301–435–1432, liangm@nida.nih.gov. Name of Committee: National Institute on Drug Abuse, Special Emphasis Panel, Diversity-promoting Institutions’ Drug Abuse Research Development Program. Date: February 25, 2010. Time: 10:30 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. Contact Person: Nadine Rogers, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, 301–402–2105, rogersn2@nida.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Diversity-promoting Institutions’ Drug Abuse Research Development Program B. Date: February 25, 2010. Time: 2 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301–402–7964, mh392g@nih.gov. Name of Committee: National Institute on Drug Abuse Initial Review Group; Training and Career Development Subcommittee. E:\FR\FM\04FEN1.SGM 04FEN1 Federal Register / Vol. 75, No. 23 / Thursday, February 4, 2010 / Notices Date: March 8–9, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892–8401, 301–451–4530, el6r@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: January 26, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–2074 Filed 2–3–10; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–5378–N–01] Notice of Proposed Information Collection: Comment Request Fair Housing Initiatives Program Grant Application and Monitoring Reports AGENCY: Office of the Assistant Secretary for Fair Housing and Equal Opportunity (FHEO), Department of Housing and Urban Development (HUD). ACTION: Notice. SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act of 1995. The Department is soliciting public comments on the subject proposal. DATES: Comment Due Date: April 5, 2010. Interested persons are invited to submit comments regarding this proposed information collection requirement. Comments should refer to the proposal by name and/or OMB Control Number, and should be sent to: Myron Newry, Director, FHIP Division, Office of Programs, Department of Housing and Urban Development, 451 Seventh Street, SW., Room 5224, Washington, DC 20410–2000. FOR FURTHER INFORMATION CONTACT: Leroy McKinney, Jr., Paperwork Reduction Act Program Manager, Office of Chief Information Officer, Department of Housing and Urban srobinson on DSKHWCL6B1PROD with NOTICES ADDRESSES: VerDate Nov<24>2008 17:31 Feb 03, 2010 Jkt 220001 Development, 451 Seventh Street, SW., Room 4178, Washington, DC 20410– 2000; telephone: 202–402–5564 (this is not a toll free number). (Hearing or speech-impaired individuals may access this number via TTY by calling the tollfree Federal Information Relay Service at: 1–800–877–8339.) SUPPLEMENTARY INFORMATION: The Department is submitting this proposed information collection requirement to the OMB for review, as required under the Paperwork Reduction Act of 1995 [44 U.S.C. Chapter 35, as amended]. Required forms were approved under Departmental clearance under the FHIP NOFA process. This notice solicits comments from members of the public and affected agencies concerning the proposed information collection in order to: (1) Evaluate whether the proposed information collection is necessary for the proper performance of the Department’s program functions; (2) Evaluate the accuracy of the Department’s assessment of the paperwork burden that may result from the proposed information collection; (3) Enhance the quality, utility and clarity of the information which must be collected; and (4) Minimize the burden of the information collection on responders, including the use of appropriate automated collection techniques or other forms of information technology (e.g., electronic transmission of data). Title of Regulation: 24 CFR Part 125, Fair Housing Initiatives Program. OMB Control Number, if applicable: 2529–0033. Description of the need for the information and proposed use: This is a revision of the currently approved information collection for selecting applicants for the Fair Housing Initiatives Program (FHIP) grants that will be part of the Notice of Funding Availability (NOFA). These grants are to fund fair housing enforcement and/or education and outreach activities under the following initiatives: Administrative Enforcement; Private Enforcement, Education and Outreach, and Fair Housing Organizations. Information is also collected to monitor grants and grant funds. Proposed revisions to the currently approved information collection include: changes in the program description from ‘‘Fair Housing Initiatives Program Grant Application’’ to ‘‘Fair Housing Initiatives Program Grant Application and Monitoring Reports.’’ Monitoring reports will continue to be submitted electronically and manually. Electronic reports include the attached forms: ‘‘Types of PO 00000 Frm 00044 Fmt 4703 Sfmt 9990 5799 Closures’’, ‘‘Bases and Issues in Tests’’, and ‘‘Basis and Issues of Reports of Discrimination.’’ Agency form number(s), if applicable: HUD 904 A, B, and C, SF–425, SF–424, SF–LLL, HUD–2880, HUD–2990, HUD– 2993, HUD–424CB, HUD–424–CBW, HUD2994–A, HUD–96010, and HUD– 27061. Members of affected public: The collection of information involves Qualified Fair Housing Organizations (QFHOs); Fair Housing Organizations (FHOs); public or private non-profit organizations or institutions and other public or private entities that are working to prevent or eliminate discriminatory housing practices; State and local governments; and Fair Housing Assistance Program Agencies. Estimation of the total numbers of hours needed to prepare the information collection including the number of respondents, frequency of response, and hours of response: An estimation of 46,420 total hours will be needed to prepare the information collection. The number of respondents is 400 with a frequency response of 1 per annum, and the total hours per respondent is 76.50 hours for application development. The estimated 104 agencies that will receive funding and have to provide quarterly and final reports, with approximately 59 having to provide Enforcement Logs and 1 agency reporting on a semi-annual basis. The estimated number of respondents is based on the average of the number of submissions for NOFA years 2008 to current. The number of hours is an average based on grantee estimates of time to review instructions, search existing data sources, prepare required responses to the application, complete the certification, and assemble exhibits. Status of the proposed information collection: Revision of a currently approved collection. Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended. Dated: January 28, 2010. Cheryl Ziegler, Deputy Assistant Secretary for Enforcement and Programs. [FR Doc. 2010–2364 Filed 2–3–10; 8:45 am] BILLING CODE 4210–67–P E:\FR\FM\04FEN1.SGM 04FEN1

Agencies

[Federal Register Volume 75, Number 23 (Thursday, February 4, 2010)]
[Notices]
[Pages 5798-5799]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-2074]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse, Special 
Emphasis Panel; International Research Collaborations on HIV/AIDS 
and Drug Use.
    Date: February 18, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Sofitel Washington DC, Lafayette Square, 806 15th Street, 
NW., Madeline Room, Washington, DC 20005.
    Contact Person: Scott Chen, PhD, Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6101 Executive Boulevard, Room 
220, MSC 8401, Bethesda, MD 20892, 301-443-9511, 
chensc@mail.nih.gov.

    Name of Committee: National Institute on Drug Abuse, Special 
Emphasis Panel, Targeted Library Synthesis and Screening at Novel 
Targets for Potential Drug Addiction (R21/R33).
    Date: February 25, 2010.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 
Bethesda, MD 20814.
    Contact Person: Minna Liang, PhD, Scientific Review Officer, 
Training and Special Projects Review Branch, Office of Extramural 
Affairs, National Institute on Drug Abuse, NIH, 6101 Executive 
Blvd., Room 220, MSC 8401, Bethesda, MD 20852, 301-435-1432, 
liangm@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse, Special 
Emphasis Panel, Diversity-promoting Institutions' Drug Abuse 
Research Development Program.
    Date: February 25, 2010.
    Time: 10:30 a.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852.
    Contact Person: Nadine Rogers, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda, MD 20892-8401, 301-402-2105, rogersn2@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Diversity-promoting Institutions' Drug Abuse 
Research Development Program B.
    Date: February 25, 2010.
    Time: 2 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852.
    Contact Person: Meenaxi Hiremath, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964, 
mh392g@nih.gov.

    Name of Committee: National Institute on Drug Abuse Initial 
Review Group; Training and Career Development Subcommittee.

[[Page 5799]]

    Date: March 8-9, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, 
Bethesda, MD 20892-8401, 301-451-4530, el6r@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)


    Dated: January 26, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-2074 Filed 2-3-10; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.